Table 2 Summary of study population for all entered patients
Analysis Population | PBO n (%) a | LY40 n (%) a | LY80 n (%) a | RIS n (%) a | Total n (%) a |
|---|---|---|---|---|---|
Randomized Patients | N = 295 | N = 293 | N = 282 | N = 143 | N = 1013 |
Completed | 171 (58.0) | 143 (48.8) | 129 (45.7) | 96 (67.1) | 539 (53.2) |
ITT Patients in the Overall Population | 295 (100.0) | 292 (99.7) | 280 (99.3) | 142 (99.3) | 1009 (99.6) |
Completed | 171 (58.0) | 143 (48.8) | 129 (45.7) | 96 (67.1) | 539 (53.2) |
Efficacy-Evaluable ITT Patients in the Overall Population | 267 (90.5) | 267 (91.1) | 253 (89.7) | 132 (92.3) | 919 (90.7) |
Completed | 154 (52.2) | 136 (46.4) | 116 (41.1) | 90 (62.9) | 496 (49.0) |
ITT Patients in the Predefined Subpopulation | 211 (71.5) | 210 (71.7) | 195 (69.1) | 98 (68.5) | 714 (70.5) |
Completed | 120 (40.7) | 107 (36.5) | 83 (29.4) | 65 (45.5) | 375 (37.0) |
Efficacy-Evaluable ITT Patients in the Predefined Subpopulation | 195 (66.1) | 189 (64.5) | 176 (62.4) | 93 (65.0) | 653 (64.5) |
Completed | 111 (37.6) | 101 (34.5) | 73 (25.9) | 61 (42.7) | 346 (34.2) |